free porn
porn
free porn

Agenda

AgendaARM’s Advanced Therapies Investor Day is a full-day conference combining discussions between key opinion leaders, top analysts and senior executives with presentations by the field’s most promising companies.

Thursday – November 3, 2016

7:30am REGISTRATION, BREAKFAST & NETWORKING
8:00am WELCOME REMARKS
Speaker:
Morrie Ruffin, Managing Director, Alliance for Regenerative Medicine (ARM)
8:15am FIRESIDE CHAT: HEMATOLOGICAL DISORDERS – ASSESSING THE CLINICAL AND COMMERCIAL LANDSCAPE FOR ATMPs
Since many of the programs closest to registration in cell and gene therapy address hematological diseases, these experts will discuss the outlook for the next 12-24 months and the major issues being addressed by companies and clinicians as these products approach the market.
Chair:
Cindy Collins, CEO, Purification and Analysis and Cell Therapy Businesses, GE Healthcare
Speakers:
Michael Linden, Ph.D., VP, Gene Therapy, Pfizer
Amit Nathwani, Ph.D., MRCP, Director, Katharine Dormandy Haemophilia Centre, Royal Free Hospital; Professor of Haematology, University College London (UCL); Chief Scientific Officer, Freeline Therapeutics
8:40am FIRESIDE CHAT: IMMUNO-ONCOLOGY
Cell-based therapies to treat, and in some cases cure, cancer as well as therapies to prevent the immune system from attacking healthy tissues in hematopoietic stem cell transplants are now in pivotal trials. What are the key challenges for successful commercialization of these products?
Chair:
Robert Preti, Ph.D., Chairman, Alliance for Regenerative Medicine (ARM); President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences
Speakers:
James Noble, Co-Founder and CEO, Adaptimmune
Manfred Rüdiger, Ph.D., CEO, Kiadis Pharma
9:05am PANEL: CELL THERAPY MANUFACTURING
Chair:
Alain Vertès, Ph.D., Director, European Section, Alliance for Regenerative Medicine (ARM)
Speakers:
Janet Downie, CEO, Roslin Cell Therapies
Thomas Fellner, Ph.D., Head of Commercial Development, Cell Therapy, Lonza
Ryan Guest, Director and Head of GMP Processing, Cellular Therapeutics Limited (CTL)
Phil Vanek, Ph.D., General Manager, Cell Therapy Growth Strategy, GE Healthcare
10:05am MORNING BREAK
10:20am COMPANY PRESENTATIONS
10:20am Adaptimmune
10:35am Kiadis Pharma
10:50am MaxCyte
11:05am PANEL: BUILDING A SUCCESSFUL ENVIRONMENT FOR TRANSLATING CELL & GENE THERAPIES
Chair:
Steve Bates, CEO, BioIndustry Association (BIA)
Speakers:
Edward Hodgkin, D.Phil., Partner, Syncona
Emma Morris, BA, MB, BChir, MA, Ph.D., MRCP, FRCPath, Professor, Clinical Cell and Gene Therapy, University College London (UCL); Honorary Consultant, Haematology and Stem Cell Transplantation, UCL Hospital and the Royal Free Hospital
Beth Thompson, Ph.D., Senior Policy Adviser, Wellcome Trust
Keith Thompson, CEO, Cell and Gene Therapy Catapult
12:05pm LUNCH & NETWORKING
1:15pm COMPANY PRESENTATIONS
1:15pm TxCell
1:30pm Abeona Therapeutics
1:45pm Oxford BioMedica
2:00pm Synpromics
2:15pm PANEL: CLINICAL PROGRESS OF GENE THERAPIES
Chair:
Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult
Speakers:
Bernard Gilly, Ph.D., Co-Founder and CEO, GenSight Biologics
Sven Kili, M.D., VP and Head of Gene Therapy Development, GlaxoSmithKline (GSK)
Nicolas Koebel, SVP Business Operations, Orchard Therapeutics
Timothy Miller, Ph.D., President, CEO and Director, Abeona Therapeutics
Silvia Priori, M.D., Ph.D., Professor of Cardiology, University of Pavia; Global Scientific Director, Director of Cardiac Rehabilitation and Director of the Molecular Cardiology Laboratories, Istituti Clinici Maugeri SpA Society for Benefit
3:15pm AFTERNOON BREAK
3:30pm COMPANY PRESENTATIONS
3:30pm ReNeuron
3:45pm Capricor Therapeutics
4:00pm CellProthera
4:15pm BioLife Solutions
4:30pm INVESTOR SESSION
Chair:
Ger Brophy, Ph.D., Chief Technology Officer, GE Healthcare
Speakers:
Marcus Baker, Director, Rothschild & Co.
Genghis Lloyd-Harris, M.D., Ph.D., Partner, Abingworth
5:00pm NETWORKING RECEPTION
6:30pm PROGRAM CLOSE